|
1
|
Maes J, Gesquière S, De Spiegeleer A, Maes
A and Van de Wiele C: Prostate-specific membrane antigen biology
and pathophysiology in prostate carcinoma, an update: Potential
implications for targeted imaging and therapy. Int J Mol Sci.
25:97552024. View Article : Google Scholar
|
|
2
|
Hyväkkä A, Virtanen V, Kemppainen J,
Grönroos TJ, Minn H and Sundvall M: More than meets the eye:
Scientific rationale behind molecular imaging and therapeutic
targeting of prostate-specific membrane antigen (PSMA) in
metastatic prostate cancer and beyond. Cancers (Basel).
13:22442021. View Article : Google Scholar
|
|
3
|
Haffner MC, Kronberger IE, Ross JS,
Sheehan CE, Zitt M, Mühlmann G, Ofner D, Zelger B, Ensinger C, Yang
XJ, et al: Prostate-specific membrane antigen expression in the
neovasculature of gastric and colorectal cancers. Hum Pathol.
40:1754–1761. 2009. View Article : Google Scholar
|
|
4
|
Van de Wiele C, Sathekge M, de Spiegeleer
B, De Jonghe PJ, Debruyne PR, Borms M, Beels L and Maes A: PSMA
expression on neovasculature of solid tumors. Histol Histopathol.
35:919–927. 2020.
|
|
5
|
Watanabe R, Maekawa M, Kiyoi T, Kurata M,
Miura N, Kikugawa T, Higashiyama S and Saika T: PSMA-positive
membranes secreted from prostate cancer cells have potency to
transform vascular endothelial cells into an angiogenic state.
Prostate. 81:1390–1401. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Watanabe R, Kagimoto K, Chosei M, Sakaue
T, Kurata M, Miura N, Kitazawa R, Kikugawa T, Higashiyama S and
Saika T: Vesicles secreted by renal cell carcinoma cells cause
vascular endothelial cells to express PSMA and drive tumor
progression. Cells. 14:1652025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Israeli RS, Powell CT, Fair WR and Heston
WD: Molecular cloning of a complementary DNA encoding a
prostate-specific membrane antigen. Cancer Res. 53:227–230.
1993.PubMed/NCBI
|
|
8
|
Bzdega T, Turi T, Wroblewska B, She D,
Chung HS, Kim H and Neale JH: Molecular cloning of a peptidase
against N-acetylaspartylglutamate from a rat hippocampal cDNA
library. J Neurochem. 69:2270–2277. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pinto JT, Suffoletto BP, Berzin TM, Qiao
CH, Lin S, Tong WP, May F, Mukherjee B and Heston WD:
Prostate-specific membrane antigen: A novel folate hydrolase in
human prostatic carcinoma cells. Clin Cancer Res. 2:1445–1451.
1996.PubMed/NCBI
|
|
10
|
Davis MI, Bennett MJ, Thomas LM and
Bjorkman PJ: Crystal structure of prostate-specific membrane
antigen, a tumor marker and peptidase. Proc Natl Acad Sci USA.
102:5981–5986. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barinka C, Rovenská M, Mlcochová P,
Hlouchová K, Plechanovová A, Majer P, Tsukamoto T, Slusher BS,
Konvalinka J and Lubkowski J: Structural insight into the
pharmacophore pocket of human glutamate carboxypeptidase II. J Med
Chem. 50:3267–3273. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu H, Rajasekaran AK, Moy P, Xia Y, Kim
S, Navarro V, Rahmati R and Bander NH: Constitutive and
antibody-induced internalization of prostate-specific membrane
antigen. Cancer Res. 58:4055–4060. 1998.PubMed/NCBI
|
|
13
|
Anilkumar G, Rajasekaran SA, Wang S,
Hankinson O, Bander NH and Rajasekaran AK: Prostate-specific
membrane antigen association with filamin A modulates its
internalization and NAALADase activity. Cancer Res. 63:2645–2648.
2003.PubMed/NCBI
|
|
14
|
Tsai G, Passani LA, Slusher BS, Carter R,
Baer L, Kleinman JE and Coyle JT: Abnormal excitatory
neurotransmitter metabolism in schizophrenic brains. Arch Gen
Psychiatry. 52:829–836. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Slusher BS, Vornov JJ, Thomas AG, Hurn PD,
Harukuni I, Bhardwaj A, Traystman RJ, Robinson MB, Britton P, Lu
XC, et al: Selective inhibition of NAALADase, which converts NAAG
to glutamate, reduces ischemic brain injury. Nat Med. 5:1396–1402.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Caromile LA, Dortche K, Rahman MM, Grant
CL, Stoddard C, Ferrer FA and Shapiro LH: PSMA redirects cell
survival signaling from the MAPK to the PI3K-AKT pathways to
promote the progression of prostate cancer. Sci Signal.
10:eaag33262017. View Article : Google Scholar
|
|
17
|
Boixareu C, Taha T, Venkadakrishnan VB, de
Bono J and Beltran H: Targeting the tumour cell surface in advanced
prostate cancer. Nat Rev Urol. 22:569–589. 2025. View Article : Google Scholar
|
|
18
|
Sedlák F, Kvasnička A, Marešová B,
Brumarová R, Dobešová D, Dostálová K, Šrámková K, Pehr M, Šácha P,
Friedecký D and Konvalinka J: Parallel metabolomics and lipidomics
of a PSMA/GCPII deficient mouse model reveal alteration of NAAG
levels and brain lipid composition. ACS Chem Neurosci.
15:1342–1355. 2024. View Article : Google Scholar
|
|
19
|
Pellegrino S and Fonti R: A look into the
future: The role of PSMA beyond prostate cancer. Eur J Nucl Med Mol
Imaging. 51:278–280. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rajasekaran SA, Anilkumar G, Oshima E,
Bowie JU, Liu H, Heston W, Bander NH and Rajasekaran AK: A novel
cytoplasmic tail MXXXL motif mediates the internalization of
prostate-specific membrane antigen. Mol Biol Cell. 14:4835–4845.
2003. View Article : Google Scholar
|
|
21
|
Zhang X, Qi S, Liu D, Du J and Jin J:
PSMA-Targeted supramolecular nanoparticles prepared from
cucurbit[8]uril-based ternary host-guest recognition for prostate
cancer therapy. Front Chem. 10:8475232022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Minner S, Wittmer C, Graefen M, Salomon G,
Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J,
et al: High level PSMA expression is associated with early PSA
recurrence in surgically treated prostate cancer. Prostate.
71:281–288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meller B, Bremmer F, Sahlmann CO, Hijazi
S, Bouter C, Trojan L, Meller J and Thelen P: Alterations in
androgen deprivation enhanced prostate-specific membrane antigen
(PSMA) expression in prostate cancer cells as a target for
diagnostics and therapy. EJNMMI Res. 5:662015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Calais J, Kishan AU, Cao M, Fendler WP,
Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, et al:
Potential impact of 68Ga-PSMA-11 PET/CT on the planning of
definitive radiation therapy for prostate cancer. J Nucl Med.
59:1714–1721. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Staal J and Beyaert R: Inflammation and
NF-κB signaling in prostate cancer: Mechanisms and clinical
implications. Cells. 7:1222018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Basílio J, Hochreiter B, Hoesel B,
Sheshori E, Mussbacher M, Hanel R and Schmid JA: Antagonistic
functions of androgen receptor and NF-κB in prostate
cancer-experimental and computational analyses. Cancers (Basel).
14:61642022. View Article : Google Scholar
|
|
27
|
Watt F, Martorana A, Brookes DE, Ho T,
Kingsley E, O'Keefe DS, Russell PJ, Heston WD and Molloy PL: A
tissue-specific enhancer of the prostate-specific membrane antigen
gene, FOLH1. Genomics. 73:243–254. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Noss KR, Wolfe SA and Grimes SR:
Upregulation of prostate specific membrane antigen/folate hydrolase
transcription by an enhancer. Gene. 285:247–256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao Y, Zheng H, Li L, Feng M, Chen X, Hao
B, Lv Z, Zhou X and Cao Y: Prostate-specific membrane antigen
(PSMA) promotes angiogenesis of glioblastoma through interacting
with ITGB4 and regulating NF-κB signaling pathway. Front Cell Dev
Biol. 9:5983772021. View Article : Google Scholar
|
|
30
|
Perico ME, Grasso S, Brunelli M,
Martignoni G, Munari E, Moiso E, Fracasso G, Cestari T, Naim HY,
Bronte V, et al: Prostate-specific membrane antigen (PSMA)
assembles a macromolecular complex regulating growth and survival
of prostate cancer cells ‘in vitro’ and correlating with
progression ‘in vivo’. Oncotarget. 7:74189–74202. 2016. View Article : Google Scholar
|
|
31
|
Ghosh A, Wang X, Klein E and Heston WD:
Novel role of prostate-specific membrane antigen in suppressing
prostate cancer invasiveness. Cancer Res. 65:727–731. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Silver DA, Pellicer I, Fair WR, Heston WD
and Cordon-Cardo C: Prostate-specific membrane antigen expression
in normal and malignant human tissues. Clin Cancer Res. 3:81–85.
1997.PubMed/NCBI
|
|
33
|
Bakht MK, Yamada Y, Ku SY, Venkadakrishnan
VB, Korsen JA, Kalidindi TM, Mizuno K, Ahn SH, Seo JH, Garcia MM,
et al: Landscape of prostate-specific membrane antigen
heterogeneity and regulation in AR-positive and AR-negative
metastatic prostate cancer. Nat Cancer. 4:699–715. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Damjanovic J, Janssen JC, Prasad V,
Diederichs G, Walter T, Brenner W and Makowski MR: 68Ga-PSMA-PET/CT
for the evaluation of liver metastases in patients with prostate
cancer. Cancer Imaging. 19:372019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mattoni S, Farolfi A, Formaggio F, Bruno
G, Caroli P, Cerci JJ, Eiber M, Fendler WP, Golfieri R, Herrmann K,
et al: PSMA PET for the evaluation of liver metastases in
castration-resistant prostate cancer patients: A multicenter
retrospective study. Cancers (Basel). 14:56802022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sayar E, Patel RA, Coleman IM, Roudier MP,
Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V, et al:
Reversible epigenetic alterations mediate PSMA expression
heterogeneity in advanced metastatic prostate cancer. JCI Insight.
8:e1629072023. View Article : Google Scholar
|
|
37
|
Hope TA, Eiber M, Armstrong WR, Juarez R,
Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, et
al: Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal
metastasis detection prior to radical prostatectomy and pelvic
lymph node dissection: A multicenter prospective phase 3 imaging
trial. JAMA Oncol. 7:1635–1642. 2021. View Article : Google Scholar
|
|
38
|
Wernicke AG, Edgar MA, Lavi E, Liu H,
Salerno P, Bander NH and Gutin PH: Prostate-specific membrane
antigen as a potential novel vascular target for treatment of
glioblastoma multiforme. Arch Pathol Lab Med. 135:1486–1489. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fragomeni RA, Amir T, Sheikhbahaei S,
Harvey SC, Javadi MS, Solnes LB, Kiess AP, Allaf ME, Pomper MG,
Gorin MA and Rowe SP: Imaging of nonprostate cancers using
PSMA-targeted radiotracers: Rationale, current state of the field,
and a call to arms. J Nucl Med. 59:871–877. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Moore M, Panjwani S, Mathew R, Crowley M,
Liu YF, Aronova A, Finnerty B, Zarnegar R, Fahey TJ III and
Scognamiglio T: Well-differentiated thyroid cancer neovasculature
expresses prostate-specific membrane antigen-a possible novel
therapeutic target. Endocr Pathol. 28:339–344. 2017. View Article : Google Scholar
|
|
41
|
Nomura N, Pastorino S, Jiang P, Lambert G,
Crawford JR, Gymnopoulos M, Piccioni D, Juarez T, Pingle SC, Makale
M and Kesari S: Prostate specific membrane antigen (PSMA)
expression in primary gliomas and breast cancer brain metastases.
Cancer Cell Int. 14:262014. View Article : Google Scholar
|
|
42
|
Bychkov A, Vutrapongwatana U, Tepmongkol S
and Keelawat S: PSMA expression by microvasculature of thyroid
tumors-Potential implications for PSMA theranostics. Sci Rep.
7:52022017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kasoha M, Unger C, Solomayer EF, Bohle RM,
Zaharia C, Khreich F, Wagenpfeil S and Juhasz-Böss I:
Prostate-specific membrane antigen (PSMA) expression in breast
cancer and its metastases. Clin Exp Metastasis. 34:479–490. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Schmidt LH, Heitkötter B, Schulze AB,
Schliemann C, Steinestel K, Trautmann M, Marra A, Hillejan L, Mohr
M, Evers G, et al: Prostate specific membrane antigen (PSMA)
expression in non-small cell lung cancer. PLoS One.
12:e01862802017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Machado CML, Skubal M, Haedicke K, Silva
FP, Stater EP, Silva TLAO, Costa ET, Masotti C, Otake AH, Andrade
LNS, et al: Membrane-derived particles shed by PSMA-positive cells
function as pro-angiogenic stimuli in tumors. J Control Release.
364:312–325. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Conway RE, Petrovic N, Li Z, Heston W, Wu
D and Shapiro LH: Prostate-specific membrane antigen regulates
angiogenesis by modulating integrin signal transduction. Mol Cell
Biol. 26:5310–5324. 2006. View Article : Google Scholar
|
|
47
|
Grant CL, Caromile LA, Ho V, Durrani K,
Rahman MM, Claffey KP, Fong GH and Shapiro LH: Prostate specific
membrane antigen (PSMA) regulates angiogenesis independently of
VEGF during ocular neovascularization. PLoS One. 7:e412852012.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li Y, Zhang K, Yang F, Jiao D, Li M, Zhao
X, Xu C, Liu S, Li H, Shi S, et al: Prognostic value of
vascular-expressed PSMA and CD248 in urothelial carcinoma of the
bladder. Front Oncol. 11:7710362021. View Article : Google Scholar
|
|
49
|
Schreiber H, Hänze J, Nimphius W, Verburg
FA, Luster M, Hofmann R and Hegele A: Prostate specific membrane
antigen (PSMA) in urothelial cell carcinoma (UCC) is associated
with tumor grading and staging. J Cancer Res Clin Oncol.
146:305–313. 2020. View Article : Google Scholar
|
|
50
|
Lin BH, Chen SH, Chen SM, Qiu QR, Gao RC,
Wei Y, Zheng QS, Miao WB and Xu N: Head-to-head comparisons of
68Ga-PSMA-11 and 18F-FDG PET/CT in evaluating patients with upper
tract urothelial carcinoma: A prospective pilot study. Int Urol
Nephrol. 55:2753–2764. 2023. View Article : Google Scholar
|
|
51
|
Liu D, Wang L and Guo Y: Advances in and
prospects of immunotherapy for prostate cancer. Cancer Lett.
601:2171552024. View Article : Google Scholar
|
|
52
|
Ge R, Wang Z and Cheng L: Tumor
microenvironment heterogeneity an important mediator of prostate
cancer progression and therapeutic resistance. NPJ Precis Oncol.
6:312022. View Article : Google Scholar
|
|
53
|
Puik JR, Le C, Kazemier G, Oprea-Lager DE,
Swijnenburg RJ, Giovannetti E, Griffioen AW and Huijbers EJ:
Prostate-specific membrane antigen as target for
vasculature-directed therapeutic strategies in solid tumors. Crit
Rev Oncol Hematol. 205:1045562025. View Article : Google Scholar
|
|
54
|
Maguid MS, Saad El Dine MG, Gabal SM and
Fandoud SM: Prostate-specific membrane antigen (PSMA) expression in
the neovasculature of high grade gliomas (Histopathological and
Immunohistochemical Study). Asian Pac J Cancer Prev. 24:1797–1808.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bellavia MC, Patel RB and Anderson CJ:
Combined targeted radiopharmaceutical therapy and immune checkpoint
blockade: From preclinical advances to the clinic. J Nucl Med.
63:1636–1641. 2022.PubMed/NCBI
|
|
56
|
Altunay B, Schäfer L, Morgenroth A, Peña
Q, Lammers T, Saar M, Mottaghy FM and Lütje S: Combining
PSMA-targeted radiopharmaceutical therapy with immunotherapy. J
Nucl Med. 28:1522–1527. 2025. View Article : Google Scholar
|
|
57
|
Jiao R and Dadachova E: Combination of
radioligand therapy and immunotherapy: How to make it work in
clinic? Immunotargets Ther. 14:755–759. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sheehan B, Guo C, Neeb A, Paschalis A,
Sandhu S and de Bono JS: Prostate-specific membrane antigen biology
in lethal prostate cancer and its therapeutic implications. Eur
Urol Focus. 8:1157–1168. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Palamiuc L and Emerling BM: PSMA brings
new flavors to PI3K signaling: A role for glutamate in prostate
cancer. J Exp Med. 215:17–19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
O'Keefe DS, Bacich DJ, Huang SS and Heston
WDW: A perspective on the evolving story of PSMA biology,
PSMA-based imaging, and endoradiotherapeutic strategies. J Nucl
Med. 59:1007–1013. 2018. View Article : Google Scholar
|
|
61
|
Wright K, Ly T, Kriet M, Czirok A and
Thomas SM: Cancer-associated fibroblasts: Master tumor
microenvironment modifiers. Cancers (Basel). 15:18992023.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Bonollo F, Thalmann GN, Kruithof-de Julio
M and Karkampouna S: The role of cancer-associated fibroblasts in
prostate cancer tumorigenesis. Cancers (Basel). 12:18872020.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
McBriar JD, Shafiian N, Scharf S, Boockvar
JA and Wernicke AG: Prostate-specific membrane antigen use in
glioma management: Past, present, and future. Clin Nucl Med.
49:806–816. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hameed MY, Gul M and Chaudhry A, Muzaffar
H, Sheikh M, Chee W, Ayyash S, Ayyash J, Al-Hindi M, Shahare H and
Chaudhry A: From oncogenesis to theranostics: The transformative
role of PSMA in prostate cancer. Cancers (Basel). 16:30392024.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hofman MS, Lawrentschuk N, Francis RJ,
Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M,
Shakher R, et al: Prostate-specific membrane antigen PET-CT in
patients with high-risk prostate cancer before curative-intent
surgery or radiotherapy (proPSMA): A prospective, randomised,
multicentre study. Lancet. 395:1208–1216. 2020. View Article : Google Scholar
|
|
66
|
de Galiza Barbosa F, Queiroz MA, Nunes RF,
Costa LB, Zaniboni EC, Marin JFG, Cerri GG and Buchpiguel CA:
Nonprostatic diseases on PSMA PET imaging: A spectrum of benign and
malignant findings. Cancer Imaging. 20:232020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sartor O, de Bono J, Chi KN, Fizazi K,
Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N,
El-Haddad G, et al: Lutetium-177-PSMA-617 for metastatic
castration-resistant prostate cancer. N Engl J Med. 385:1091–1103.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kratochwil C, Bruchertseifer F, Rathke H,
Bronzel M, Apostolidis C, Weichert W, Haberkorn U, Giesel FL and
Morgenstern A: Targeted α-therapy of metastatic
castration-resistant prostate cancer with 225Ac-PSMA-617: Dosimetry
estimate and empiric dose finding. J Nucl Med. 58:1624–1631. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Sridaran D, Bradshaw E, DeSelm C,
Pachynski R, Mahajan K and Mahajan NP: Prostate cancer
immunotherapy: Improving clinical outcomes with a multi-pronged
approach. Cell Rep Med. 4:1011992023. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ettala O, Malaspina S, Tuokkola T, Luoto
P, Löyttyniemi E, Boström PJ and Kemppainen J: Prospective study on
the effect of short-term androgen deprivation therapy on PSMA
uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with
treatment-naïve prostate cancer. Eur J Nucl Med Mol Imaging.
47:665–673. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Vaz S, Hadaschik B, Gabriel M, Herrmann K,
Eiber M and Costa D: Influence of androgen deprivation therapy on
PSMA expression and PSMA-ligand PET imaging of prostate cancer
patients. Eur J Nucl Med Mol Imaging. 47:9–15. 2020. View Article : Google Scholar : PubMed/NCBI
|
